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Abstract
The purpose of the present study was to evaluate the enhancement of tolbutamide (TBM) oral bioavailability and
hypoglycaemic activity through complexation with b-cyclodextrin (b-CD) and hydroxypropyl-b-cyclodextrin (HP-b-
CD). TBM and its freeze-dried inclusion complexes were administered to rabbits (New zealand breed; n6), in a
dose of 20 mg:kg. TMB plasma levels were measured by HPLC and glucose levels were analysed according to Trinder
(Trinder, P., 1969. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann.
Clin. Biochem. 6, 24–28). The pure drug attained a maximum of plasma concentration (Cmax) of 18.5893.27 mg:ml
at 8.5 h (Tmax), whereas with inclusion complexes, Cmax increased about two times and appeared at ca. 4 h. AUC0–24
of complexes was about 1.6 times as much as that of the pure drug. Thus, the extent of oral absorption of TBM from
inclusion complexes was significantly greater and faster when compared with drug alone. In addition, without
cyclodextrins the maximum hypoglycaemic effect (CVGmax) of TBM (34.1%) was observed at 5.6 h (Tgmax). CVGmax
of TBM:b-CD and TBM:HP-b-CD inclusion complexes were 34.1% (at 6.5 h) and 37.7% (at 5.1 h), respectively.
AAC0–24 of inclusion complexes was 1.4 times larger than that of pure drug. Hence, the oral administration of
complexed TBM not only improved the drug absorption, but also the TBM hypoglycaemic activity. © 2000 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Cyclodextrins (CDs) are cyclic oligosaccharides,
containing six (a-CD), seven (b-CD) or eight (g-
CD) a-1,4-linked D-glucose units, with a hy-
drophilic outer surface and a hydrophobic cavity,
in which may be included a great variety of ‘guest’
molecules of suitable size and shape, resulting in a
stable association without formation of covalent
bonds (Szejtli, 1990). In the pharmaceutical field
this phenomenon has been extensively applied to
enhance the solubility, dissolution rate and
bioavailability of slightly soluble drugs in gas-
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trointestinal fluids (Vila-Jato et al., 1988; Soliman
et al., 1997; Ventura et al., 1997; Dhanaraju et al.,
1998; O8 zdemir and Ordu, 1998; Mura et al.,
1999).
Among the cyclodextrins, b-CD is the most
useful compound for drug complexation. How-
ever, the relatively low aqueous solubility of b-CD
(about 1.8% w:v, at 25°C) suggested the use of
chemically-modified CDs with different physical
properties and inclusion behaviour. In particular,
hydroxypropyl-b-cyclodextrin (HP-b-CD) is
widely used, because of its amorphous nature,
high water solubility and solubilising power and
low toxicity (Pitha and Pitha, 1985; Brewster,
1991).
Tolbutamide (TBM) is used as an oral hypogly-
caemic agent. The drug is practically insoluble
in water and its dissolution is supposed to
be the rate-limiting step for its absorption from
the gastrointestinal tract (Miralles et al., 1982).
Several studies on commercial brands of tolbu-
tamide dosage forms have shown marked varia-
tions in dissolution rate and bioavailability
(Carminetsky, 1963; Varley, 1968; Ayres et al.,
1984).
We previously reported (Veiga et al., 1996) that
the solubility and dissolution rate of TBM is
markedly increased due to complexation with b-
CD and HP-b-CD. These preliminary studies
suggested that the TBM oral bioavailability could
be improved through complexation with these
CDs.
The objective of the present study was to evalu-
ate the influence of the complexation on the
bioavailability and hypoglycaemic activity of
tolbutamide after oral administration to rabbits of
TBM:b-CD and TBM:HP-b-CD complexes when
compared with pure drug.
2. Material and methods
2.1. Materials
Tolbutamide (Sigma), b-CD (Roquette Fre`res)
and HP-b-CD with a molar substitution of 0.39
(Janssen) were used as received. All other reagents
and solvents were of analytical grade.
2.2. Inclusion complex preparation
The inclusion complexes of TBM:b-CD (1:2)
and TBM:HP-b-CD (1:1) were prepared by the
freeze-drying method, previously described by
Veiga et al. (1996). Stoichiometric quantities of
TBM and CDs were dissolved in distilled water
with a small amount of ammonia 25% to aid the
active ingredient to dissolve. The solution was
frozen by immersion in a shell freezer and freeze-
dried over 24 h in a Lyph-lock 6 apparatus (Lab-
conco). No trace of ammonium was detected in
the resulting mixture with Nessler reagent.
2.3. In 6i6o studies
Male rabbits (New zealand breed) were used
with an average weight of 3.5 kg. They were kept
on a standard diet (702 GR, Rico Gado) and
made to fast for 12 h prior to experiments. At
least 15 days were allowed to elapse between the
administrations.
The three formulations (commercial tolbu-
tamide, TBM:b-CD and TBM:HP-b-CD inclu-
sion complexes) with a dose of 20 mg:kg of
tolbutamide or equivalent were previously sus-
pended in 30 ml of water. The aqueous suspen-
sions were given by intragastric tubing. The
administration scheme is given in Table 1.
Table 1
Administration scheme of TBM alone, TBM:b-CD and TBM:HP-b-CD inclusion complexes
4th Set3rd SetAnimals 2nd Set1st Set
Control TBM:HP-b-CDGroup I TBM:b-CDTBM
ControlGroup II TBM:HP-b-CDTBM TBM:b-CD
TBMGroup III TBM:b-CD TBM:HP-b-CD Control
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The blood samples (1 ml) were collected over a
period of 24 h from the marginal ear vein. EDTA
was added to the blood samples to prevent clot-
ting and subsequently, plasma was obtained by
centrifugation at 2800 rev.:min for 15 min. The
plasma samples were stored at 30°C until
analysis.
2.4. Determination of TBM plasma le6els
The plasma levels of TBM were measured by
high-performance liquid chromatography
(HPLC).
2.4.1. HPLC conditions
HPLC equipment consisted of a Gilson 305
pump, Rheodyne injector (with a 20-ml loop),
Gilson 117 UV spectrometric detector, Kipp and
Zonen register and a Li-Chrospher RP 18 re-
versed-phase column (10 mm particle size, 250
4.6 mm i.d., Jones). A guard column (Jones),
similarly packed, was used before the analytical
column. The mobile phase was prepared by de-
gassing and filtering (through 0.45-mm mem-
branes, Millipore) a mixture of acetonitrile and
0.05% phosphoric acid (45:55). The chro-
matograph was operated at a flow rate of 1.5
ml:min and the eluent was monitored spectropho-
tometrically at the UV maximum of TBM (226
nm). The sample injection size was 20 ml. All the
determinations were performed at room tempera-
ture (2092°C).
2.4.2. HPLC method 6alidation
Standard curves for TBM were developed in
the mobile phase and in the rabbit plasma, for the
TBM range of 1–60 mg:ml. For construction of
standard curves in plasma, different volumes (5–
300 ml) of a 100 mg:ml TBM methanolic solution
were used. After methanol evaporation, 200 ml of
rabbit plasma and 500 ml of acetonitrile were
added. The mixtures were vortexed for 10 s and
subsequently centrifuged at 2500 rev.:min for 1
min.
TBM recovery from plasma was determined
with two concentrations (n3) by comparing the
peak areas obtained for TBM plasma samples and
those of TBM phase mobile solutions. Recoveries
of TBM from plasma samples with 20 and 40
mg:ml concentrations were 98.7 and 99.1%,
respectively.
Validation of HPLC method was evaluated by
linearity, precision (repeatability and intermediate
precision), accuracy and limit of detection. The
calibration curve of TBM was linear over the
concentration range of 1–60 mg:ml (r\0.999).
The repeatability was evaluated by six replicate
determinations of solutions with two different
concentrations of TBM. The RSD obtained for 20
and 40 mg:ml TBM solutions were 1.9 and 1.63%,
respectively. The intermediate precision was deter-
mined by analysing these solutions in five consec-
utive days. The RSD were 2.86% (20 mg:ml) and
2.27% (40 mg:ml). The accuracy, expressed as
recovery percentage of TBM from plasma, was
assessed by spiking plasma samples with TBM in
20 mg:ml concentration. The mean recovery for
six replicate plasma samples was compared with
the absolute recovery (100%) and the statistical
analysis, performed with Student’s t-test, demon-
strated that this difference was statistically not
significant (PB0.05). The detection limit for the
assay was estimated at 1 mg:ml.
2.5. Determination of plasma glucose
The glucose levels were analysed according to
Trinder (1969) using the glucose enzymatic
reagent system (glucose oxidase:peroxidase
method), in an auto-analyser (Pronto BPC
Biosed).
Plasma glucose levels (Glyc) were transformed
into the plasma glucose variation coefficient
(GVC) according to the expression:
GVC 
Glyc. at t – Glyc. at t0
Glyc. at t0
100
2.6. Pharmacokinetics and pharmacodynamics
The pharmacokinetic and pharmacodynamic
parameters were calculated using a statistical and
analytical computer programme (PKCALC, Soft-
ware Arts).
The areas under TBM plasma concentration–
time curves (AUC0–24 and AUC 0–), calculated
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Fig. 1. TBM plasma concentration–time profiles after admin-
istration of TBM, TBM:b-CD and TBM:HP-b-CD inclusion
complexes (equivalent to TBM 20 mg:kg) to rabbits (n6).
Each point represents the mean9S.D.
3. Results and discussion
Plasma concentration–time profiles for TBM
after oral administration of drug alone to rabbits,
TBM:b-CD and TBM:HP-b-CD inclusion com-
plexes (equivalent dose of TBM 20 mg:kg) are
illustrated in Fig. 1. The pharmacokinetic
parameters derived from the plasma data are pre-
sented in Table 2. The plasma levels of TBM after
administration of inclusion complexes were clearly
faster and higher than those achieved with an
equal TBM dose given alone. In particular, the
Cmax after administration of TBM alone was ob-
served at 8.5 h; on the other hand, TBM com-
plexes resulted in the rapid appearance of TBM in
plasma, attaining the Cmax after ca. 4 h. In addi-
tion, the value of Cmax for the complexes (36.269
2.17 and 34.9991.36 mg:ml to b-CD and
HP-b-CD complexes, respectively) was about two
times greater that of TMB alone (18.5893.27
mg:ml). The differences in the mean of Cmax and
Tmax between the TBM and the complexes were
statistically significant (PB0.05), but no signifi-
cant differences in these plasma parameters were
observed between the two types of complexes. A
similar trend was observed with the t1:2, in which
there was a significant difference (PB0.05) only
between TBM alone and the inclusion complexes.
The high t1:2 values can be attributed to the
strong and extensive binding of TBM to plasma
proteins, in animals and humans (about 96%)
(Tillement, 1983).
The AUC0–24 of complexes was found to be
about 1.6-fold greater than the TBM alone. Simi-
larly, AUC0– for the complexes was 1.4 times as
much as that from reference TBM. The statistical
by the linear trapezoidal method, the maximum
plasma concentration of the drug (Cmax), the time
to reach Cmax (Tmax) and TBM elimination half-
life (t1:2) were chosen as parameters for pharma-
cokinetic evaluation. The relative bioavailability
between the inclusion complexes and commercial
drug was calculated from the ratio of their AUC
values.
The area above the curve of glucose variation
coefficient (GVC) versus time (AAC0–24), calcu-
lated by linear trapezoidal rule, the percent maxi-
mum of GVC depression (GVCmax) and the time
to reach GVCmax (Tgmax) were selected as parame-
ters for pharmacodynamic evaluation.
Statistical analysis of results was performed
using one-way analysis of variance (ANOVA) and
the least-significant difference test (LSD) at 95%
of confidence (PB0.05).
Table 2
Pharmacokinetic parameters and relative bioavailability of TBM after oral administration of TBM, TBM:b-CD and TBM:HP-b-CD
inclusion complexes (equivalent to TBM 20 mg:kg) to rabbitsa
System Cmax (mg:ml) AUC0–24Tmax (h) AUC0– T1:2 (h) Rel. bioavailability
(mg h:ml) (mg h:ml) (%)
18.5893.27 12.4891.33TBM 443.96963.33312.95947.218.5091.15
3.8390.6536.2692.17b-CD complex 8.7990.47621.62952.73516.26945.05 165.00
510.76928.2234.9991.36 4.0090.45 10.2291.19654.63962.42HP-b-CD 163.21
complex
a Each value represents the mean9S.D. for six rabbits.
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Fig. 2. Drug absorption mechanism involving cyclodextrin
complexation, adapted from Uekama and Otagiri (1987).
greater when the complex has a smaller stability
constant. The complex with a very small
stability constant is diluted in the biological
fluids after administration, which results in a
quick dissociation of the complex with little or no
effect on its overall absorption properties. On the
contrary, if the complex is very stable or the
cyclodextrin concentration is sufficiently high, the
equilibrium is shifted greatly toward complexa-
tion and the absorption is considered hindered. In
the present study, since the Ks values of
complexes are relatively low and of the same
magnitude (195.7 and 144.8 M1 to TBM:b-CD
and TBM:HP-b-CD complexes, respectively)
(Veiga et al., 1996), it seems very unlikely that
they have some negative influence in complex
dissociation. Then, we can conclude that the solu-
bility, dissolution rate and Ks magnitude of the
complexes are not the only limiting factors of
TMB absorption.
Simultaneously with the determination of TBM
plasma levels, the corresponding hypoglycaemic
effects were monitored up to 24 h. The hypogly-
caemic response, expressed as glucose variation
coefficient (GVC), and the pharmacodynamic
parameters are presented in Fig. 3 and Table 3,
respectively.
study demonstrated that there were significant
differences in these areas between TBM and the
complexes (PB0.05), while the differences of the
two complexes were statistically insignificant. This
enhancement in TBM AUCs can be attributed to
the increase in TBM solubility and dissolution
rate upon complexation with CDs. However, this
improvement in TBM bioavailability was clearly
independent of the cyclodextrin employed in com-
plexation, although the solubility of TMB was
2.5-fold higher in HP-b-CD complexes than in the
b-CD complexes, as previously reported (Veiga et
al., 1996).
Since only the free form of the drug can pass
through the lipid barrier of the gastrointestinal
tract, after oral administration of cyclodextrin
complex, the drug absorption is conditioned by
the equilibrium between the free and complexed
drug (Fromming, 1987; Uekama and Otagiri,
1987). Therefore, the effect of cyclodextrin com-
plexation on drug absorption is largely dependent
upon the magnitude of the stability constant (Ks)
as well as the solubility and dissolution rate of the
inclusion complex. This overall process can be
described by the scheme shown in Fig. 2 proposed
by Uekama and Otagiri (1987). In this scheme,
the rate constant for the dissolution of the solid
complex and stability constant of the complex in
the fluids at the absorption side are represented by
Kd and Kc, respectively; Ka is the rate constant for
the passage of the free form of the drug across the
biomembrane. Obviously, the free drug concen-
tration that may be available for absorption is
Fig. 3. Glucose variation coefficient–time profiles after admin-
istration of TBM, TBM:b-CD and TBM:HP-b-CD inclusion
complexes (equivalent to TBM 20 mg:kg) to rabbits (n6).
Each point represents the mean9S.D.
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The GVC profiles, like TBM plasma profiles,
were practically coincident for b-CD and HP-b-
CD inclusion complexes. In the absence of CDs,
the TBM hypoglycaemic effect was observed with
a maximum of 30.55% (CVGmax) at 5.7 h (Tgmax),
after administration of TBM alone. Although the
CVGmax was increased upon CD complexation
(34.0791.01 and 37.6791.48% to b-CD and
HP-b-CD inclusion complexes, respectively), only
the enhancement caused by HP-b-CD was statisti-
cally significant. The analysis of variance of the
areas above the glucose variation coefficient ver-
sus time (AAC0–24) demonstrated that there was a
significant difference between the AAC0–24 of
TBM alone and the inclusion complexes. How-
ever, the AAC0–24 ratio of the hypoglycaemic
effect between the complexes and TBM (about
1.4) was smaller than the corresponding ratio
(AUC0–24) of TMB plasma levels (about 1.6).
The mean values of Tgmax were greater for
TBM:b-CD inclusion complexes than for pure
drug and TBM:HP-b-CD, but statistical analysis
showed that this difference was not significant.
Since Tgmax values were similar in the three sys-
tems, the pharmacodynamic response was not de-
pendent on TBM absorption rate.
The enhanced hypoglycaemic effect displayed
by the improvement of TBM bioavailability re-
vealed that there was a correlation between the
TBM plasma levels and the hypoglycaemic re-
sponse. This correlation is clearly evident by com-
paring Fig. 2 and Fig. 4, in which one seems to be
the mirror image of the other. The complexation
with cyclodextrins promoted an enhanced and
faster TBM oral absorption, but only increased
the hypoglycaemic effect, without any influence
on its rate. The absence of proportional relation
between TMB plasma concentration and pharma-
codynamic effect was also observed by Balant
(1981). For this reason, it is common that in TBM
and other sulphonylurea studies, the pharmacody-
namic effect is evaluated instead of the determina-
tion of drug plasma concentrations (Vila-Jato et
al., 1987; Kedzierewicz et al., 1993; Torres-Laban-
deira et al., 1994; Babu and Pankit, 1995).
4. Conclusion
Reference TBM demonstrated its poor pharma-
cokinetic and bioavailability performance follow-
ing oral administration. Administration of the
TBM inclusion complexes was characterised by an
oral absorption pattern that was faster and more
efficient than that of TBM alone. A correlation
between TBM plasma levels and hypoglycaemic
effect was achieved. The pharmacodynamic evalu-
ation clearly indicated that TBM hypoglycaemic
activity was promoted when complexed with CDs,
although without affecting the time for reaching
the maximum effect.
The enhanced bioavailability and correspond-
ing potentiation of hypoglycaemic activity by CD
complexation of TBM suggests a dose decrease in
oral sulphonylurea therapy with reduction of side
effects. With the growing acceptance of CDs as
excipients and the presence of CD in formulations
rapidly approaching regulatory approval, these
pharmacokinetic and pharmacodynamic studies
might be beneficial in generating dosage forms not
only for TBM but also for a variety of other
drugs (Brewster et al., 1997).
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